[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491161":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":30,"centralContacts":36,"locations":46,"responsibleParty":62,"collaborators":30,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":30,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":30,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":30,"overallStatus":49,"whyStopped":30,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Hospital for Special Surgery, New York","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Low-dose PRP","EXPERIMENTAL","Patients will receive a single injection of 6 ml low-dose platelet-rich plasma (PRP) into the glenohumeral joint. Low-dose is defined as a platelet yield of 3X (i.e., 3-fold increase in platelets in PRP compared to whole blood).",[13],"Biological: Low-dose PRP",{"label":15,"type":10,"description":16,"interventionNames":17},"High-dose PRP","Patients will receive a single injection of 6 ml high-dose platelet-rich plasma (PRP) into the glenohumeral joint. High-dose is defined as a platelet yield of 12X (i.e., 12-fold increase in platelets in PRP compared to whole blood).",[18],"Biological: High-dose PRP",{"label":20,"type":21,"description":22,"interventionNames":23},"Saline control","PLACEBO_COMPARATOR","Patients will receive a single injection of 6 ml saline into the glenohumeral joint.",[24],"Other: Saline",[26,31,33],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":30},"BIOLOGICAL","Injection",[9],null,{"type":27,"name":15,"description":28,"armGroupLabels":32,"otherNames":30},[15],{"type":6,"name":34,"description":28,"armGroupLabels":35,"otherNames":30},"Saline",[20],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":30,"email":41},"Jonathan Kirschner, MD","CONTACT","646-714-6327","kirschnerj@hss.edu",{"name":43,"role":39,"phone":44,"phoneExt":30,"email":45},"Jennifer Cheng","646-714-6870","chengj@hss.edu",[47],{"facility":48,"status":49,"city":50,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Hospital for Special Surgery","RECRUITING","New York","10021","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-74.00597,40.71427,{"lat":58,"lon":57},[61],{"name":38,"role":39,"phone":30,"phoneExt":30,"email":41},{"type":63,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100491161","phase-4-prp-for-glenohumeral-osteoarthritis-100491161",false,"NCT05675527","PRP for Glenohumeral Osteoarthritis","Outcomes Following Single Injections of Low-dose Platelet-rich Plasma (PRP), High-dose PRP, or Saline in Patients With Glenohumeral OA: a Randomized Controlled Trial","Inclusion Criteria:\n\n* 18-100 years old\n* Average NRS pain greater than or equal to 5\u002F10 as a direct result of glenohumeral osteoarthritis (any severity: mild, moderate, or severe) and\u002For chondral lesion or loss\n* At least 3 months of pain after onset of symptoms that has failed conservative treatments, including physical therapy\n* MRI of the affected joint\n* Transient relief of symptoms after a diagnostic intra-articular injection into the joint\n* Email address or network access\n\nExclusion Criteria:\n\n* Inability to hold non-steroidal anti-inflammatory drugs for 2 weeks prior and 1 month after the injection\n* Prior platelet-rich plasma injection\n* Steroid injection within 3 months of the initial injection\n* Hyaluronic acid within 6 months of the initial injection\n* Involved in workers' compensation or active litigation involving the affected joint\n* History of Plavix use\n* Known uncontrolled systemic illness (uncontrolled diabetes, HIV, vasculitis, autoimmune\u002Fautoinflammatory disease)\n* Presence of acute fractures or gross mechanical deformities\n* Concurrent \"uncontrolled\" cervical disorders","ALL","18 Years","100 Years",{"count":75,"type":76},135,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.",[82],"Shoulder Osteoarthritis","2025-10-01",{"date":85,"type":86},"2025-10-06","ACTUAL",{"date":88,"type":86},"2023-05-02",{"date":90,"type":76},"2026-09-01",{"name":5,"class":6},1]